CVS Pharmacy Inc. was named Feb. 1 in a lawsuit that contends the retailer has engaged in unfair and deceptive practices through the marketing and sale of a dietary supplement known as Algal-900 DHA.
At the heart of the proposed class-action case is whether the consumption of omega-3 fatty acids contained in CVS’s product is capable of bolstering one’s memory.
The Algal-900 DHA product package features in capital letters, “CLINICALLY SHOWN MEMORY IMPROVEMENT.” The package also touts the product as the “only DHA form & dosage clinically shown to improve memory.”
